Abstract
Despite recent advances in diagnosis and treatment of certain cancers such as breast, colon and prostate cancers, pancreatic cancer remains a deadly malignancy with a mortality rate almost equal to its incidence. The survival benefit after all possible medical interventions is still disappointing for the majority of patients with pancreatic cancer. Improving the quality of life and increasing survival remain as the key objectives of pharmacogenomics and clinical investigation in pancreatic cancer. There are several notable genetic loci (e.g., RRM1, CDA, DPYD, UGT1A1) known to predict the toxicity of drugs used in pancreatic cancer such as gemcitabine, capecitabine, platinum agents and irinotecan. Other genes are associated with efficacy of these drugs (e.g., HuR, DCK, TS, ERCC1), although prospective validation of their clinical utility is still required. This paper presents the latest research advances in pharmacogenomics of pancreatic cancer with a view to molecular guidance for clinical diagnosis and individualized patient care.
Keywords: Early diagnosis, genomics, pancreatic cancer, postgenomics medicine, targeted oncopharmacology
Current Pharmacogenomics and Personalized Medicine
Title: Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Volume: 8 Issue: 1
Author(s): A. S. Strimpakos, C. Hoimes, K. N. Syrigos and M. W. Saif
Affiliation:
Keywords: Early diagnosis, genomics, pancreatic cancer, postgenomics medicine, targeted oncopharmacology
Abstract: Despite recent advances in diagnosis and treatment of certain cancers such as breast, colon and prostate cancers, pancreatic cancer remains a deadly malignancy with a mortality rate almost equal to its incidence. The survival benefit after all possible medical interventions is still disappointing for the majority of patients with pancreatic cancer. Improving the quality of life and increasing survival remain as the key objectives of pharmacogenomics and clinical investigation in pancreatic cancer. There are several notable genetic loci (e.g., RRM1, CDA, DPYD, UGT1A1) known to predict the toxicity of drugs used in pancreatic cancer such as gemcitabine, capecitabine, platinum agents and irinotecan. Other genes are associated with efficacy of these drugs (e.g., HuR, DCK, TS, ERCC1), although prospective validation of their clinical utility is still required. This paper presents the latest research advances in pharmacogenomics of pancreatic cancer with a view to molecular guidance for clinical diagnosis and individualized patient care.
Export Options
About this article
Cite this article as:
S. Strimpakos A., Hoimes C., N. Syrigos K. and W. Saif M., Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?, Current Pharmacogenomics and Personalized Medicine 2010; 8 (1) . https://dx.doi.org/10.2174/1875692111008010073
DOI https://dx.doi.org/10.2174/1875692111008010073 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Interaction Domains: Structural Features and Drug Discovery Applications (Part 2)
Current Medicinal Chemistry PET Imaging with [<sup>68</sup>Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [<sup>18</sup>F]Fluorodeoxyglucose and [<sup>18</sup>F]Fluoroethylcholine
Current Cancer Drug Targets Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine The Role of Non-coding Genome in Cancer-associated Fibroblasts; Stateof- the-Art and Perspectives in Cancer Targeted Therapy
Current Drug Targets Aquaporins as Targets for Drug Discovery
Current Pharmaceutical Design Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis
Current Pharmaceutical Biotechnology Cancer Molecular Imaging: Radionuclide-Based Biomarkers of the Epidermal Growth Factor Receptor (EGFR)
Current Topics in Medicinal Chemistry Bisphosphonates as Treatment of Bone Metastases
Current Pharmaceutical Design Functional Peptides and Small Molecules in Medicinal Chemistry-Part I
Current Topics in Medicinal Chemistry Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets Computer-Aided Drug Design for AMP-Activated Protein Kinase Activators
Current Computer-Aided Drug Design Editorial: [Hot Topic: Chromogranin A at the Crossroads of Health and Disease]
Current Medicinal Chemistry Nanotechnology in Neuroscience and its Perspective as Gene Carrier
Current Topics in Medicinal Chemistry Fibroblast Activation Protein in Remodeling Tissues
Current Molecular Medicine Deciphering Transcriptional Regulation Relevant to Eating Behavior
Current Genomics Identifying Molecular Biomarker for the Lung Squamous Cell Carcinoma by Integrating Multifactorial Data
Current Bioinformatics Molecular Modeling Used to Evaluate CYP2C9-Dependent Metabolism: Homology Modeling, Molecular Dynamics and Docking Simulations
Current Drug Metabolism Understanding and Applying Personalized Therapeutics at Systems Level:Role for Translational Bioinformatics
Current Pharmacogenomics and Personalized Medicine Herbal Medicine in the Treatment of Cancer
Current Medicinal Chemistry - Anti-Cancer Agents